Biofrontera Inc. Sets Record with Strong Q4 2025 Results, Paves Way for Future Growth
On March 19, 2026, Biofrontera Inc., a leading company in the dermatology community, announced its fourth quarter and full-year 2025 financial results, showcasing a strong performance that marks a new milestone for the company.
The conference call transcript revealed that Biofrontera achieved record annual revenues of $41.7 million, representing a 12% growth over the prior year. This success was capped by a record fourth quarter, with revenues reaching $17.1 million, marking an approximately 36% year-over-year growth.
"Fiscal year 2025 was a transformational year for Biofrontera," said Hermann Luebbert, CEO, Chairman, and Founder of the company. "I'm proud to say that we delivered record annual revenues, demonstrating the strength of our commercial execution and the growing adoption of Ameluz PDT across the dermatology community."
The Q4 2025 results were highly profitable for Biofrontera Inc., with an Adjusted EBITDA of $4.9 million and an additional capital gain of $700K from the Xepi divestment, resulting in a net income of $5.6 million.
The acquisition of all U.S. rights, approvals, and patents for Ameluz and RhodoLED was one of the most significant milestones in Biofrontera's history, giving the company full regulatory control in the United States. This transaction also led to a new royalty or earn-out structure, replacing the previous transfer pricing model.
The new royalty structure is 12% when annual U.S. Ameluz net sales are at or below $65 million and 15% in years where they exceed that threshold. This change reflects the company's growth potential and its ability to adapt to changing market conditions.
Biofrontera's strong Q4 2025 results demonstrate the company's commitment to delivering value to its stakeholders. With a solid foundation established, the company is poised for continued growth and success in 2026 and beyond."
